Acquisition / mergerNotableFiled on BSE ·

Biocon board approves acquisition of BBL shares via share swap and debenture conversion

Biocon · Pharmaceuticals & Biotechnology

Arthneeti Research DeskPublished 1 min read

Key highlights

  • Biocon to acquire up to 1,15,36,956 BBL shares for 87,92,317 Biocon shares issued at ₹376.16 each, worth ₹330.73 crore, subject to shareholder approval.
  • Board approved conversion of 1,125 OCDs of BBL into 4,11,11,689 BBL equity shares and of 1,06,86,044 CCDs of BBL into an equal number of BBL equity shares.
  • Board recommended S. R. Batliboi & Associates LLP as statutory auditors for five years from the 48th AGM on August 6, 2026, replacing B S R & Co. LLP, subject to shareholder approval.

Why it's rated notable: amount is ₹500 crore or more

Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.

Original filing

Announcement under Regulation 30 (LODR)-Acquisition

Read the filing on BSE (PDF) →

Companies guiding to strong growth

Ranked by management's own guidance on revenue and margins — not by us.

Rossell Techsys

Aerospace & Defense

Revenue growth 40%+Margin up 2%+

Sign up free to see all 6 →

See full rankings

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

More from Biocon

Other acquisition / merger filings this fortnight

All acquisition / merger filings →

Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.